Frédérique Penault-Llorca

12PUBLICATIONS
57CO-AUTHORS
Molecular targetsEnvironmental epidemiologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Neurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 09, 2026
Identification of ribosomal protein eL21 as a novel externalized protein and a target in triple-negative breast cancer.

Lucie Arnould, Nina Radosevic-Robin, Laura Duranton

|Aug 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.

Enora Laas, Anne-Sophie Hamy, Thomas Bachelot

|Aug 22, 2025
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.

François-Clément Bidard, Grégoire Gessain, Thomas Bachelot

|Mar 24, 2025
Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations.

Frédérique Penault-Llorca, Mark A Socinski

|May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Thomas Bachelot, Paul Cottu, Sylvie Chabaud

|Jul 21, 2021
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.

Sunil S Badve, Frédérique Penault-Llorca, Jorge S Reis-Filho

Pageof 2

Frequent Collaborators

3 joint publications

Jerome Lemonnier

2 joint publications

Fabrice Andre

2 joint publications

Sunil S Badve

2 joint publications

Sylvie Giacchetti